Results 11 to 20 of about 47,423 (289)
Mirodenafil Prevents Bladder Dysfunction Induced by Chronic Bladder Ischemia in Rats [PDF]
International Neurourology Journal, 2015 Purpose: To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Methods: Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group ...
Hoon Choi +5 more
doaj +1 more source
Phosphodiesterase Inhibitors: Present and Future
Barcelona Respiratory Network Reviews, 2023 Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj +1 more source
Pulmonary Circulation, 2020 Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz +6 more
doaj +1 more source
A review of phosphodiesterase type 5 inhibitors
South African Family Practice, 2014 Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction.
N. Schellack, A. Agoro
doaj +1 more source
PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS
International Journal of Clinical Practice, 2002 SUMMARYThe clinical properties (efficacy and safety profile) of a medicine are related not only to its mode of action, but also to its selectivity for its target (usually a receptor or enzyme) and are also influenced by its pharmacokinetic properties (absorption, distribution, metabolism and elimination).
J D, Corbin, S H, Francis
openaire +2 more sources
Phosphodiesterase type 5 inhibitors and erectile dysfunction
South African Family Practice, 2010 Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management
Catherine Whittaker
doaj +1 more source
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review
Journal of Ophthalmic & Vision Research, 2021 Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso +2 more
doaj +1 more source
Phosphodiesterase 5 inhibitors for pulmonary hypertension [PDF]
Cochrane Database of Systematic Reviews, 2017 Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right-heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left-heart disease (PH-LHD ...
Hayley, Barnes +3 more
openaire +3 more sources
Journal of Research in Pharmacy Practice, 2015 Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are ...
Nahid Eskandari +5 more
doaj +1 more source
Pulmonary Circulation, 2020 Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson +8 more
doaj +1 more source